NASDAQ:CNST Constellation Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Constellation Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $19.71 +0.27 (+1.39 %) (As of 09/28/2020 04:42 PM ET) Add Compare Share Today's Range$18.92Now: $19.71▼$20.0950-Day Range$17.62MA: $22.46▼$27.8952-Week Range$6.01Now: $19.71▼$59.49Volume467,860 shsAverage Volume516,321 shsMarket Capitalization$936.23 millionP/E RatioN/ADividend YieldN/ABeta2.9 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. It is also developing CPI-0209, which is in preclinical trials for the treatment of solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingConstellation Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $43.56, Constellation Pharmaceuticals has a forecasted upside of 118.3% from its current price of $19.95.Amount of Analyst CoverageConstellation Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.4 Community Rank Outperform VotesConstellation Pharmaceuticals has received 112 “outperform” votes. (Add your “outperform” vote.)Underperform VotesConstellation Pharmaceuticals has received 122 “underperform” votes. (Add your “underperform” vote.)Community SentimentConstellation Pharmaceuticals has received 52.14% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Constellation Pharmaceuticals and other stocks. Vote “Outperform” if you believe CNST will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CNST will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldConstellation Pharmaceuticals does not currently pay a dividend.Dividend GrowthConstellation Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Constellation Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.60% of the stock of Constellation Pharmaceuticals is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Constellation Pharmaceuticals are expected to decrease in the coming year, from ($2.75) to ($3.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Constellation Pharmaceuticals is -7.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Constellation Pharmaceuticals is -7.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioConstellation Pharmaceuticals has a P/B Ratio of 2.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.35 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CNST Previous Symbol CUSIP21036U206 CIK29806 Webwww.constellationpharma.com Phone617-714-0555Debt Debt-to-Equity Ratio0.06 Current Ratio19.17 Quick Ratio19.17Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.23 per share Price / Book2.39Profitability EPS (Most Recent Fiscal Year)($3.04) Net Income$-85,550,000.00 Net MarginsN/A Return on Equity-34.28% Return on Assets-28.48%Miscellaneous Employees82 Outstanding Shares47,500,000Market Cap$936.23 million Next Earnings Date11/4/2020 (Estimated) OptionableNot Optionable $19.71 +0.27 (+1.39 %) (As of 09/28/2020 04:42 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CNST News and Ratings via Email Sign-up to receive the latest news and ratings for CNST and its competitors with MarketBeat's FREE daily newsletter. Constellation Pharmaceuticals (NASDAQ:CNST) Frequently Asked Questions How has Constellation Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)? Constellation Pharmaceuticals' stock was trading at $32.57 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CNST shares have decreased by 39.5% and is now trading at $19.71. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Constellation Pharmaceuticals? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Constellation Pharmaceuticals. When is Constellation Pharmaceuticals' next earnings date? Constellation Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Constellation Pharmaceuticals. How were Constellation Pharmaceuticals' earnings last quarter? Constellation Pharmaceuticals Inc (NASDAQ:CNST) announced its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.64) by $0.06. View Constellation Pharmaceuticals' earnings history. What price target have analysts set for CNST? 10 Wall Street analysts have issued 1 year target prices for Constellation Pharmaceuticals' shares. Their forecasts range from $20.00 to $75.00. On average, they expect Constellation Pharmaceuticals' stock price to reach $43.56 in the next twelve months. This suggests a possible upside of 121.0% from the stock's current price. View analysts' price targets for Constellation Pharmaceuticals. Are investors shorting Constellation Pharmaceuticals? Constellation Pharmaceuticals saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 3,600,000 shares, a decrease of 15.5% from the August 15th total of 4,260,000 shares. Based on an average daily trading volume, of 668,500 shares, the days-to-cover ratio is currently 5.4 days. View Constellation Pharmaceuticals' Short Interest. Who are some of Constellation Pharmaceuticals' key competitors? Some companies that are related to Constellation Pharmaceuticals include Turning Point Therapeutics (TPTX), ChemoCentryx (CCXI), Amicus Therapeutics (FOLD), HYPERA S A/S (HYPMY), Insmed (INSM), Principia Biopharma (PRNB), Global Blood Therapeutics (GBT), SAGE Therapeutics (SAGE), PTC Therapeutics (PTCT), Reata Pharmaceuticals (RETA), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), GW Pharmaceuticals PLC- (GWPH), Schrodinger (SDGR) and Axsome Therapeutics (AXSM). View all competitors. What other stocks do shareholders of Constellation Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Applied Materials (AMAT), Inovio Pharmaceuticals (INO), Intel (INTC), Pfizer (PFE), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO), NVIDIA (NVDA) and AT&T (T). Who are Constellation Pharmaceuticals' key executives? Constellation Pharmaceuticals' management team includes the following people: Mr. Jigar Raythatha, Pres, CEO & DirectorMs. Emma Reeve, Sr. VP, CFO Treasurer & Sec. (Age 58)Dr. Adrian M. Senderowicz, Sr. VP & Chief Medical Officer (Age 55)Dr. Danny Reinberg Ph.D., Co-FounderDr. Yang Shi Ph.D., Co-Founder When did Constellation Pharmaceuticals IPO? (CNST) raised $80 million in an initial public offering on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager. What is Constellation Pharmaceuticals' stock symbol? Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST." Who are Constellation Pharmaceuticals' major shareholders? Constellation Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Great Point Partners LLC (7.33%), Vanguard Group Inc. (3.53%), Venrock Management V LLC (3.28%), Regents of The University of California (2.95%), Deerfield Management Company L.P. Series C (1.84%) and Victory Capital Management Inc. (1.82%). Company insiders that own Constellation Pharmaceuticals stock include Adrian Senderowicz, Anthony B Evnin, Emma Reeve, Group L P Column, James E Audia, Karen Valentine, Mark A Goldsmith, Of The University Of C Regents and Patrick Trojer. View institutional ownership trends for Constellation Pharmaceuticals. Which major investors are selling Constellation Pharmaceuticals stock? CNST stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., FMR LLC, Regents of The University of California, Deerfield Management Company L.P. Series C, P.A.W. Capital Corp, Alps Advisors Inc., AQR Capital Management LLC, and Strs Ohio. Company insiders that have sold Constellation Pharmaceuticals company stock in the last year include Adrian Senderowicz, Emma Reeve, James E Audia, Karen Valentine, Mark A Goldsmith, Of The University Of C Regents, and Patrick Trojer. View insider buying and selling activity for Constellation Pharmaceuticals. Which major investors are buying Constellation Pharmaceuticals stock? CNST stock was acquired by a variety of institutional investors in the last quarter, including Venrock Management V LLC, Great Point Partners LLC, Vanguard Group Inc., Jennison Associates LLC, Candriam Luxembourg S.C.A., Goldman Sachs Group Inc., Sofinnova Investments Inc., and Venrock Partners Management V LLC. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Anthony B Evnin, and Group L P Column. View insider buying and selling activity for Constellation Pharmaceuticals. How do I buy shares of Constellation Pharmaceuticals? Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Constellation Pharmaceuticals' stock price today? One share of CNST stock can currently be purchased for approximately $19.71. How big of a company is Constellation Pharmaceuticals? Constellation Pharmaceuticals has a market capitalization of $936.23 million. The company earns $-85,550,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis. Constellation Pharmaceuticals employs 82 workers across the globe. What is Constellation Pharmaceuticals' official website? The official website for Constellation Pharmaceuticals is www.constellationpharma.com. How can I contact Constellation Pharmaceuticals? Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected] This page was last updated on 9/28/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
